Introduction
The NF-kB/Rel family of transcription factors regulates the expression of a variety of genes, including many involved in the regulation of immune and in¯ammatory responses, cellular proliferation, dierentiation, and inhibition of apoptosis (reviewed in Ghosh et al., 1998; Siebenlist et al., 1994; Verma et al., 1995) . The proteins that comprise the NF-kB/Rel family have a region of homology of approximately 300 amino acids at their amino-termini, called the Rel Homology Domain (RHD), which confers DNA-binding properties, dimerization with other NF-kB proteins, and nuclear localization. There are two subfamilies of NF-kB/Rel proteins, the Rel proteins and the NF-kB proteins. The Rel proteins, including the viral oncoprotein v-Rel, its cellular homologue c-Rel, Rel A p65, and Rel B, contain potent transcriptional activation domains in their Ctermini. The NF-kB subfamily is comprised of two genes, NFKB1 and NFKB2. These genes encode large protein products, p105 NF-kB-1, and p100 NF-kB2, which are retained in the cytoplasm where they function as repressors of NF-kB activity (Blank et al., 1991; Henkel et al., 1992; Mercurio et al., 1992; Naumann et al., 1993b; Rice et al., 1992; Scheinman et al., 1993) . The C-termini of these proteins consist of seven tandemly repeated ankyrin domains. NFKB1 and NFKB2 also encode two shorter proteins, p50 NF-kB-1 and p52 NF-kB-2, which are composed of the Nterminal RHD sequences without the C-terminal ankyrin domains, and which do not contain discrete transcriptional activation domains. p50 NF-kB-1 and p52 NF-kB-2 are formed as a result of proteolysis, likely by the ubiquitin-proteasome pathway (Palombella et al., 1994) . This processing, leading to the removal of the tandem ankyrin repeats of the p105 NF-kB-1 and p100 NF-kB-2 precursor proteins, is dependent on glycine-rich sequences lying distal to the RHDs in these proteins (Lin and Ghosh, 1996) . Recent data suggest that the Tpl-2 protein kinase can induce phosphorylation and degradation of NF-kB1 p105, resulting in generation of active nuclear NF-kB (Belich et al., 1999) . p50 NF-kB-1 and p52 NF-kB-2 are also generated by a direct co-translational processing event, in which the nascent, ankyrin-containing, precursor proteins are subjected to proteasomal cleavage during translation, resulting in formation of p50 and p52, independent of production of the full-length gene products (Heusch et al., 1999; Lin et al., 1998) .
NF-kB/Rel proteins bind DNA and aect transcription as homo-and heterodimers. The classic, inducible NF-kB transcriptional activator is composed of the heterodimer of p50 NF-kB-1 and p65 RelA molecules Baltimore, 1988, 1989) . Homodimers of p50 NF-kB-1 and p52 NF-kB-2, which lack a discrete transcriptional activation domain, generally exhibit transcriptional repression properties, presumably through binding to kB motifs in the promoters of target genes and inhibiting binding of the strongly activating NF-kB dimers (Franzoso et al., 1992; Fujita et al., 1992; Schmid et al., 1991) . Interestingly, a small subset of NFkB target genes can be directly transcriptionally activated by these homodimers, apparently as a result of conformational changes in the proteins induced upon binding to speci®c subsets of kB DNA motifs (Fujita et al., 1992; Pan and McEver, 1995) .
The functions of the NF-kB/Rel dimers are regulated by the inhibitory IkB proteins (reviewed in May and Ghosh, 1997; Verma et al., 1995) . In the classic model of NF-kB activation, stimulation of cells by extracellular signals, such as tumor necrosis factor-a (TNF-a), results in activation of a kinase cascade leading to phosphorylation of speci®c regulatory serines near the amino terminus of the IkBa or IkBb by the IkB kinases (reviewed in May and Zandi and Karin, 1999) . Phosphorylation tags the IkB molecules for ubiquitination and degradation by the proteasome, allowing NF-kB dimers to translocate to the nucleus and activate the target gene transcription (DiDonato et al., 1997; Mercurio et al., 1997; Reginer et al., 1997; Zandi et al., 1997) . As noted above, the C-terminal ankyrin repeat portions of the p105 NF-kB-1 and p100 NF-kB-2 molecules convey IkB-like activities to these proteins, and p100 NF-kB-2 has been previously shown to have important IkB-like activity both in vitro and in vivo (Blank et al., 1991; Henkel et al., 1992; Mercurio et al., 1992; Naumann et al., 1993b; Rice et al., 1992; Scheinman et al., 1993) .
The NF-kB/Rel proteins play important roles in the regulation of lymphocyte activation and proliferation and have been implicated in the development of a number of human tumors, particularly leukemias and lymphomas (reviewed in Gerondakis et al., 1998; Gilmore et al., 1996; Kopp and Ghosh, 1995; Luque and GeÂ linas, 1997; Rayet and GeÂ linas, 1999) . Rearrangements of the NFKB2 gene have been associated with both B-cell and T-cell malignancies, and NF-kB-2 was identi®ed to be rearranged in up to 15 ± 20% of cutaneous T-cell lymphomas (CTCL) [(Fracchiolla et al., 1993; Migliazza et al., 1994; Neri et al., 1991; Thakur et al., 1994) and reviewed in (Neri et al., 1996) ]. The molecular structures of several tumorassociated NFKB2 alleles have been described (Fracchiolla et al., 1993; Migliazza et al., 1994; Neri et al., 1991; Thakur et al., 1994; Zhang et al., 1994) . These proteins all exhibit truncations of the C-terminal ankyrin repeats present in p100 NF-kB-2. The Lyt-10/Ca variant of NFKB2 was identi®ed from a case of B-cell non-Hodgkin's lymphoma (RC685) (Neri et al., 1991) and is a chimeric protein in which the ®rst ankyrin repeat of NF-kB-2 is fused in frame to a 174 amino acid alternative reading frame derived from the immunoglobulin Ca gene. The HUT78 p80HT (also referred to as p85, as well as p84, an alternatively spliced form of the protein), was derived from a CTCL cell line, and is a truncated form of NF-kB-2 that maintains ®ve ankyrin repeats fused to repetitive DNA sequences (Thakur et al., 1994; Zhang et al., 1994) , resulting in the fusion of the ®rst 666 amino acids of p100 NF-kB-2 to three extra amino acids (serinealanine-serine) derived from the fusion sequence.
EB308 is also derived from a CTCL patient and contains a fusion of three and a half ankyrin repeats derived from NF-kB-2 with an additional twelve amino acids at its C-terminus (Migliazza et al., 1994) . The LB40 protein was cloned from a case of B-cell chronic lymphocytic leukemia (B-CLL) and is the longest truncated protein, having its breakpoint within the sixth ankyrin repeat (Migliazza et al., 1994) . Although the actual C-terminal sequence of each of these proteins is distinct, the common C-terminal deletions suggest that this alteration may be important in altering the function of the NF-kB-2 proteins.
The mechanisms by which these NFKB2 gene rearrangements contribute to the development of lymphomas remain unclear. Altered NF-kB-2 proteins have been reported to have acquired novel transcriptional activation properties (Chang et al., 1995; Zhang et al., 1994) and the ability to transform Balb 3T3 mouse ®broblasts (Ciana et al., 1997) . Alternatively, tumor-associated NFKB2 rearrangements also result in loss of the IkB-like activities of the p100 wild-type protein (Thakur et al., 1994; Zhang et al., 1994) , possibly leading to enhanced constitutive NF-kB activation in tumor cells. In either case, NFKB2 gene rearrangements would be hypothesized to result in altered expression of NF-kB target gene expression. Therefore, we wished to further study the properties of lymphoma-associated NFKB2 alleles in the regulation of promoters whose expression is dependent upon NF-kB.
Results
Regulatory effects of wild-type NF-kB-2 gene products and tumor-associated p80HT expression on NFKB2 and IL-6 kB site promoter activity As the NFKB2 promoter was previously shown to contain several NF-kB binding sites (Liptay et al., 1994; Lombardi et al., 1995) , we hypothesized that the NFKB2 promoter could itself represent a target promoter whose expression is altered by the loss of p100 NF-kB-2 and/or the new synthesis of p80HT NFkB-2. The genomic structure and sequence of the NFKB2 gene revealed the presence of two distinct promoter regions (P1 and P2) each containing several functional kB motifs (Liptay et al., 1994; Lombardi et al., 1995) . Cotransfection of p52 NF-kB-2 with RelA resulted in a dose-dependent activation of the NFKB2 promoters (Liptay et al., 1994) or biphasic response [activation and then repression with increasing amounts of p52 ]. These results strongly suggested that transcription of NFKB2 is autoregulated. Given the very high levels of NFKB2 RNA present in HUT78 cells which are missing p100 NF-kB-2 and synthesize the truncated p80HT, we wished to determine the eects of these alternative NF-kB-2 proteins on the function of the NFKB2 P1 and P2 promoters. In order to characterize the speci®c autoregulatory eects of dierent NFKB2 gene products, we molecularly cloned the NFKB2 promoter region. We con®rmed the published P1 transcription start site by primer extension analysis, used PCR to subclone a 589 bp segment 5' to the P1 transcription start site and demonstrated that this sequence was sucient to confer full regulation of the NFKB2 promoter in response to phorbol esters (data not shown), as previously reported by others (Liptay et al., 1994; Lombardi et al., 1995) . A PCR approach was also used to speci®cally subclone a 624 bp segment of the P2 promoter including the published functional NF-kB sites.
To address the hypothesis that the high levels of NFKB2 gene expression in HUT78 cells may re¯ect altered activities of NF-kB-2 proteins in these cells, we performed a series of transient transfection assays. The eects of the wild-type p100 and p52 NF-kB-2 proteins were compared with those of the truncated p80HT (Figure 1a) . Plasmids containing the NFKB2 P1 and P2 promoters directing expression of the chloramphenicol acetyl transferase (CAT) gene were cotransfected into COS7 cells with dierent NF-kB-2 and RelA expression plasmids. As p52 and RelA (p65) were previously shown to activate in the NFKB2 promoter, we initially examined the eects of the dierent NF-kB-2 proteins on RelA activation of the P1 and p2 promoters (Figure 1b, c) . RelA alone resulted in eightfold activation of the P1 promoter (Figure 1b) . Cotransfection with RelA and either p52 or p80HT resulted in a biphasic pattern of transcriptional activation, similar to that previously described for RelA and p52 cotransfection . In contrast, p100 NF-kB2 was strongly repressive of RelA activation of P1, exhibiting a dosedependent reduction of p65 activation to background levels at higher amounts of transfected p100 expression plasmid. This is consistent with the known eects of p100 as an`IkB-like' repressor of NF-kB activation.
RelA also strongly activated transcription from the NFKB2 P2 promoter (11-fold, Figure 1c ). Again, p100 was strongly repressive of p65 activation in a dose dependent manner. p52 NF-kB-2 actually exhibited a similar strong inhibitory eect on P2-directed gene expression, leading to almost complete repression of P2 promoter activity at higher levels of transfection (similar to the previous data from Lombardi et al., 1995) . In contrast, p80HT expression resulted in a maximal reduction of RelA activation by only approximately 2 ± 3-fold, leaving strong persistent residual activation of the P2 promoter by p65 even at the highest levels of p80HT expression. These data strongly suggested that p80HT may have reduced inhibitory activity on certain kB motif containing promoters, as compared either with p100 or p52 NF-kB-2. The eect of each NF-kB-2 protein alone on the P1 and P2 promoters was also examined. All three NF-kB-2 proteins appeared to exhibit similar levels of repression of the basal transcriptional activities of both the P1 and P2 promoters in COS7 cells (data not shown); no evidence of independent transcriptional activation of these promoters by any of these NF-kB-2 proteins was observed. These results suggest that the loss of the potent inhibitory properties of p100 may play a role in overexpression of NFKB2 observed in the HUT78 cell line.
In order to test whether the dierential eects of p80HT and p100 NF-kB-2 on NF-kB-2 promoter activity could be seen for other promoters containing NF-kB motifs, and thus represented general eects on RelA-mediated transcription, we examined the function of a reporter gene plasmid in which the CAT gene was under the control of the IL-6 kB motifs. The pIL6-kB-CAT reporter plasmid contains three copies of the kB motif derived from the IL-6 promoter (Shimizu et al., 1990) directing expression of the CAT gene from the original IL-6 basal promoter. The pIL6-kB-CAT plasmid exhibited very high basal activity in COS7 cells (data not shown). We therefore chose to cotransfect pIL6-kB-CAT CAT with NF-kB-2 expression plasmids into N-tera 2 cells which have lower levels of constitutive NF-kB activity and therefore were capable of exhibiting RelA induced transcriptional activation. As was seen with the NFKB2 P1 and P2 promoters, RelA activated transcription directed by the IL-6 kB motif by approximately 17-fold ( Figure 1d ). Cotransfection of p100 completely ablated RelAmediated transcriptional activation. Interestingly, cotransfection with p52 also demonstrated a profound inhibition of RelA-induced transcriptional activation, presumably by competition for binding to the promoter by non-transactivating p52 homodimers, blocking activation induced by RelA-containing dimers. p80HT also inhibited IL-6 kB promoter activation, but was markedly less inhibitory than p100. No independent transcriptional activation was seen with cotransfection of any NF-kB-2 plasmid in the absence of RelA (Figure 1e ).
Role of NF-kB-2 C-terminal sequences in transcriptional regulation
The fact that p80HT no longer exhibited the strong inhibition of RelA mediated transcriptional activation associated with p100 NF-kB-2, suggested that Cterminal sequences within the p100 NF-kB-2 ankyrin region played a role in the inhibitory eect. This hypothesis was also consistent with the known function of ankyrin repeat-containing IkBs as inhibitors of NFkB activation. We therefore investigated the role of Cterminal ankyrin sequences in the repression of RelA activation of the NFKB2 P1 promoter. We constructed a series of C-terminal truncation mutants ( Figure 2a) acids (aa) of each protein is shown on the right. (b) Eects of NF-kB-2 proteins on RelA-mediated activation of the NFKB2 P1 promoter. The indicated amounts (0.03, 0.1, 0.3, and 1.0 mg) of each expression plasmid for p52, p80HT, and p100, respectively, were cotransfected into COS7 cells with 1 mg of P1-CAT reporter plasmid and 0.1 mg of RelA expression plasmid, using calciumphosphate coprecipitation-mediated DNA transfection. (c) Eects of NF-kB-2 proteins on RelA-mediated activation of the NFKB2 P2 promoter. The indicated amounts (0.03, 0.1, 0.3, and 1.0 mg) of each expression plasmid for p52, p80HT, and p100, respectively, were cotransfected into COS7 cells with 1 mg of P2-CAT reporter plasmid and 0.1 mg of RelA expression plasmid. (d) Eects of NFkB-2 proteins on RelA-mediated activation of the IL-6 kB promoter. One microgram of p52, p80HT and p100-expressing plasmids and 0.1 mg of p65 Rel A-expressing plasmid (pCMV-p65) were cotransfected into N-tera 2 cells with 1.0 mg of the pIL6-kB-CAT reporter plasmid by lipfection, as described in Materials and methods. (e) Eects of NF-kB-2 proteins on expression of the IL-6 kB promoter. The indicated amounts (0.3 and 1.0 mg) of each expression plasmid for p52, p80HT, and p100 or pCMV-p65 (0.1, 0.3, and 1.0 mg) was cotransfected into N-tera 2 cells with the pIL6-kB-CAT reporter plasmid (1 mg) by lipofection. The total amount of transfected DNA in all transfections was maintained constant by adding the appropriate amount of the empty expression vector, pcDNA1Amp. The averages of triplicate transfections with standard deviations are shown using PCR to generate plasmids containing these premature terminations. We were initially interested in whether the C-terminal truncation of 234 amino acids from p100 was itself sucient to induce loss of repression, or whether the short fusion domain (serinealanine-serine, SAS) at the end of p80HT, played a role in its transcriptional regulatory properties. For this purpose, we constructed plasmid aa666, which contains the identical C-terminal truncation as p80HT, without the SAS residues. Additional further C-terminal deletions (aa659, aa625, aa552, Figure 2a ) were constructed to evaluate the eects of further deletions of ankyrin repeat units. Plasmids expressing these Cterminal deletions of p100 NF-kB-2 were cotransfected with a RelA expression plasmid and with the P1-CAT (Figure 2b ) or pIL-6-kB-CAT reporter plasmids (Figure 2c ). The fold inhibition of RelA activation that was induced by each co-transfected NF-kB-2 plasmid is shown. As previously observed, p100 strongly inhibited transcription of both P1 CAT (approximately 20-fold inhibition, Figure 2b ) and pIL-6-kB-CAT (approximately tenfold inhibition, Figure 2c) and p80HT inhibited RelA activation by less than twofold for each promoter (Figure 2b,c) . Surprisingly, simple deletion of the C-terminal 234 amino acids of p100 including the two C-terminal ankyrin repeats (aa666-without the additional SAS sequences present in the lymphoma associated form) resulted in inhibition of RelA mediated activation, fully equivalent to the inhibition seen with p100 NF-kB-2 (Figure 2b,c) . Further C-terminal truncations of NFkB2 to aa659 and to aa625 also resulted in strong inhibition of RelA activation. An NF-kB-2 protein containing only two C-terminal ankyrin repeats (aa 552) was even more inhibitory than p100 itself, exhibiting 25 ± 30-fold inhibition of both the P1 and IL-6 kB promoters. These results strongly suggest that the SAS residues acquired as part of the chromosomal rearrangement that generated p80HT, play an important role in the loss of transcriptional inhibition observed with p80HT. Truncation of p100 alone was not sucient to induce loss of inhibitory activity.
These results suggested that the C-terminal SAS residues in p80HT might play a role in the loss of inhibition of RelA-mediated activation. In order to assess the role of these amino acids, additional mutated forms of NF-kB2 were generated by PCR. aa666AAA and aa666DAD replaced the two serine residues with alanine or aspartic acid, respectively ( Figure 2a ). As shown in Figure 2b ,c, aa666AAA was markedly inhibitory of RelA activation of both promoters, at levels comparable to those seen for aa666 or with p100 NF-kB-2. While aa666DAD reduced IL-6 kB promoter activity (approximately ninefold, equivalent to the reduction seen with p100), replacement of the serines with aspartic acid residues did seem to somewhat relieve the inhibitory activity on the P1 promoter (approximately fourfold repression). These data indicate that the serine residues in p80HT play an important role in the loss of inhibition of RelA activation. Given the diering eects of the aspartic acid substitutions on the two dierent promoters (assayed in two dierent cell types), a speci®c role phosphorylation of these serines is not clear, however. Either serine phosphorylation or changes in p80 conformation induced by the serine residues may play a role in altering the functions of p100 in repressing NF-kB-mediated transcription.
In order to con®rm that the mutated NF-kB-2 proteins could be produced in vivo, Western blot analysis using a mouse monoclonal antibody directed against amino acids 1 ± 444 of p52 NF-kB-2, was performed on cell extracts prepared from COS7 cells transiently transfected with the dierent mutant NFkB2-expression plasmids (Figure 2d ). Endogenous p52 and p100 were detected in all lanes including cells transfected with a vector control (pcDNA1Amp). Transfection of the p52 expression plasmid resulted in increased expression of p52 as predicted, as well as of two larger NF-kB-2-reactive bands, whose exact structure is not clear, but which have also been observed by other investigators following transient transfection of p52 expression plasmids (Betts and Nabel, 1996; Naumann et al., 1993a) . Transfection of all of mutated NF-kB-2 plasmids resulted in synthesis of NF-kB-2 polypeptides whose sizes were consistent with those predicted based on the position of the introduced C-terminal truncations, and consistent with sizes previously observed in in vitro transcription/ translation of the various mutants (data not shown). Although there was some variability in levels of protein synthesis, this was unlikely to account for dierences of repression of RelA activation seen in Figure 2b ,c. For example, while the levels of AA625, AA666, p80HT, and AA666AAA were all essentially comparable, only p80HT exhibited the signi®cant loss of the ability to repress RelA-mediated transcription. Similarly, while AA552 appeared to have been expressed at somewhat lower levels, it exhibited strong repression of RelA transcriptional evaluation. Of note was the presence of a prominent additional band of approximately 85 kD following transfection of AA552, as well as all of the plasmids expressing longer forms of NF-kB-2, including that encoding p100. While the nature of this band is not clear at present, it was also detected with an additional antibody against N-terminal NF-kB-2 sequences, however failed to react with antisera directed against the C-terminus of the p100 NF-kB-2 protein (data not shown). This 85 kD band was also previously observed by other groups (Betts and Nabel, 1996; Naumann et al., 1993a) .
Transcriptional activity of lymphoma-associated rearranged NF-kB-2 proteins
The results observed for p80HT suggested that loss of inhibition of NF-kB-mediated transcriptional activation was an important characteristic of this lymphomaassociated protein. Furthermore, signi®cant dierences in transcriptional regulatory activity were observed between the lymphoma-associated form (p80HT, aa666SAS), and a direct truncation at the same position (aa666), suggesting that the actual amino acid composition of the lymphoma-associated form played a role in its altered activity. We therefore were interested in studying the eects of additional lymphomaassociated forms of NF-kB-2 on regulation of NFkB-mediated transcription. In these experiments, we compared the properties of the tumor associated Lyt10/Ca, EB308, p80HT, and LB40 mutants. While LB40 itself is a direct truncation of NF-kB-2 sequences, the other three mutants all have 3' fusions generating chimeric proteins. Based on our studies of p80HT, we were also interested in examining the properties of mutated forms of the Lyt10/Ca and EB308 proteins which had direct truncations in place of fusion sequences present at the C-termini of these proteins. The structures of each of the tumorassociated mutants, as well as of the direct truncations generated by PCR-mediated mutagenesis are shown in Figure 3a . Each of these NF-kB-2 mutants was assayed, as previously described, for eects on RelAmediated activation of kB-responsive promoters. All of the tumor-associated mutants as well as the corresponding direct C-terminal truncations of NF-kB-2 were less inhibitory of RelA-mediated activation of the P1 NFKB2 promoter than was the wild-type p100 protein, which exhibited over 17-fold reduction of P1 activity (Figure 3b ). Among the tumor-associated mutants, p80HT was the least inhibitory molecule (approximately twofold reduced expression, comparable to that observed with p52), and as previously noted, was signi®cantly less inhibitory than the direct truncation, aa666. Lyt10/Ca as well as its corresponding truncation mutant were also only mildly inhibitory of RelA activation, however the tumor associated EB308 and LB40 were more inhibitory (7 ± 8-fold), although still less so than p100 itself. Assays using the IL-6 kB promoter (Figure 3c ) similarly showed that p80HT, Lyt10/Ca, and LB40 were signi®cantly less inhibitory of RelA-mediated activation, as compared to p100. In contrast, the lymphoma-associated 3' altera- Expression of p100 NF-kB-2 C-terminal truncation and point mutants. Western blot analysis using antisera directed against the RHD of p52 was performed following transfection of wild-type and mutated plasmids into COS7 cells. Molecular weight standards (MW) are shown on the left. The bands corresponding to the endogenous p100 and p52 proteins are indicated by arrows. The bands corresponding to the predicted NF-kB-2 proteins expressed from the transfected wild-type and mutant expression plasmids are indicated with asterisks (*) tion found in the EB308 mutation, as well as the direct truncation at aa605 (missing the 12 amino acid fusion domain present in EB308) remained strongly repressive of RelA-induced transcription, and in fact, were more inhibitory than p100. Thus, while all four lymphomaassociated NF-kB-2 variants exhibited loss of inhibitory activity on at least one NF-kB-responsive promoter (the NFKB2 P1 promoter), at least one tumor associated truncation retained a potent inhibitory phenotype on another NF-kB target promoter (IL-6 kB). None of the tumor-associated mutants, or their corresponding truncations, exhibited independent transcriptional activation of either the P1 promoter or the IL-6 kB promoter (data not shown).
Western blot analysis was performed to con®rm that all of the NF-kB mutants used in these studies could also be produced in vivo. Lysates from HeLa cells transiently transfected with the dierent tumor-associated NF-kB-2 forms, as well as the corresponding truncation mutants, were assayed for the presence of NF-kB-2 proteins by incubation with monoclonal anti-human p52 antibody (Figure 3d) . Transfection of all of mutated NF-kB-2 plasmids resulted in synthesis of NF-kB-2 polypeptides whose sizes were consistent with those predicted based on the position of the termination codons and the presence or absence of fusion peptide sequences. Similar results were also observed in Western blot analysis of transfected COS7 cells (data not shown). 
Discussion
Alterations of the structure and/or functions of members of the NF-kB/Rel family of transcription factors have been implicated in development and progression of several dierent human malignancies (Gilmore et al., 1996; Luque and GeÂ linas, 1997; Rayet and GeÂ linas, 1999) . In several cases of human B-and T-cell lymphomas, genetic rearrangements at chromosome 10q24 are associated with structural alterations of the NFKB2 gene, resulting in production of truncated NFkB-2 proteins with heterogeneous C-terminal ends (Fracchiolla et al., 1993 ; Migliazza et al., 1994; Neri et al., 1991 Neri et al., , 1996 Thakur et al., 1994) . Such alterations have been particularly associated with cutaneous T cell lymphomas; anywhere from 3 ± 5% to 15 ± 20% of CTCL samples have been reported to have NFKB2 gene alterations (Migliazza et al., 1994; Thakur et al., 1994) . Our laboratory and others (Thakur et al., 1994; Zhang et al., 1994) have examined in detail the nature of the altered NF-kB-2 proteins present in the HUT78 CTCL cell line. These cells express alternate forms of a truncated NF-kB-2 precursor protein of 80 ± 85 KD molecular weight. Rearrangement of the NFKB2 allele was associated with high levels of constitutive NF-kB activity, expression of large amounts of the p80HT truncated precursor NF-kB-2 protein, as well as the processed p52 NF-kB-2, and a marked overexpression of NF-kB-2 mRNA (Thakur et al., 1994) . We were interested in determining if the high levels of NF-kB-2 RNA in HUT78 cells were a direct consequence of altered NFKB2 gene autoregulation as a result of the production of p80HT and the loss of p100 NF-kB-2 in these cells. In analyses of the two dierent NFKB2 promoters, P1 and P2, we failed to see any evidence of independent transcriptional activation mediated directly by p80HT. Thus, although p80HT has been previously reported to have acquired novel transcriptional activation properties not associated with p52 (Chang et al., 1995) , it appears that the NFKB2 promoter is not itself activated by p80HT. In contrast, we observed that p100 NF-kB-2, previously reported to have`IkB-like' properties in inhibiting NF-kB-mediated transcriptional activation (Blank et al., 1991; Henkel et al., 1992; Mercurio et al., 1992; Naumann et al., 1993b; Rice et al., 1992; Scheinman et al., 1993) , was also a potent inhibitor of both the P1 and P2 NFKB2 promoters. This led us to hypothesize that the constitutive, high levels of transcription of the NF-kB-2 promoter could be due to the loss of p100 inhibitory activity, rather than due to a gain of function due to the generation of the p80HT protein.
In this model of NFKB2 gene regulation, production of high levels of NFKB2 gene products, for example in response to T cell activation stimuli Thakur et al., 1994) and p52/p65 dimers, would lead to increased levels of p100 NF-kB-2, which would in turn repress NF-kB-2 transcription leading to a shut-o of gene expression. This would provide tight control over the levels of these gene products. In this scenario, the loss of p100 in the HUT78 cells would lead to loss of the repressive activity, resulting in constitutive overexpression of NF-kB-2 RNA and protein products. It is likely that careful control of NFKB2 gene expression is important for normal homeostasis and development, as two distinct mechanisms have apparently been evolved to repress its expression. These include the autorepressive eects of p100 and the repressive eects on NFKB2 gene expression mediated by the RBPJk protein, which represses basal expression, but is overridden by NF-kB activation (Oswald et al., 1998) . Our studies further highlighted the role of p100 as an inhibitor of NF-kB-induced gene expression, not only of the NFKB2 promoter, but also of a promoter directd by the IL-6 NF-kB motifs. p80HT also displayed a loss of the inhibitory activity associated with p100 for this promoter as well. These results led us to investigate the sequence alterations in p80HT that were responsible for the loss of inhibitory activity. A simple hypothesis was that the mere deletion of C-terminal ankyrin sequences disrupted the structure of the ankyrin repeat containing region, resulting in the loss of inhibitory activity. Studies using a series of C-terminal deletion mutants of p100 demonstrated that simple deletion of ankyrin sequences was not sucient to eliminate the inhibitory eect. In fact, a C-terminally deleted NF-kB-2 precursor, containing as few as two ankyrin motifs (aa 552) was sucient to fully inhibit p65-mediated activation of kB motifcontaining promoters. On the other hand continued deletion to aa490 (half of one ankyrin motif), or to aa512 containing a single ankyrin motif (data not shown), resulted in reduced inhibitory activity to the levels seen with p52 alone. Thus, the integrity of the entire ankyrin region was not required for the IkB-like eects of p100. This is distinct from the phenotype observed for isolated C-terminus of p105 NF-kB-1, in which six ankyrin domains and the adjacent acidic region were required for IkB-like activity (Hatada et al., 1993) . Similarly, this is also dierent from the properties of IkBa, in which either 5' or 3' deletions of the central ankyrin repeat domain, as well as the deletion of the C-terminal acidic region resuletd in a loss of IkB activity (Hatada et al., 1993; Inoue et al., 1992; Jaray et al., 1995; Luque and GeÂ linas, 1998) . Predictions made from the X-ray crystallographic structures of trimeric p50-p65-IkBa complexes Jacobs and Harrison, 1998; Malek et al., 1998) further identi®ed interactions of distinct ankyrin domains with DNA binding and nuclear localization regions. It is possible that the dierent ankyrin domains of p100 could also dierentially interact with regions of NF-kB dimers required for DNA binding and for nuclear localization, with two ankyrin domains being sucient to inhibit either process, thus giving an inhibitory phenotype. In this regard, in our experiments, transient overexpression of either p80HT or aa666, as well as of wild-type p100, all demonstrated nuclear expression of NF-kB-2-immunoreactive proteins as monitored by immuno¯uorescence, concurrent with inhibition of RelA transcriptional activation. Furthermore, neither in vitro translated homodimers of p80HT nor aa666 showed signi®cant binding to the IL-6 kB DNA motif (data not shown), implying that direct competition of aa666 dimers with RelA for binding to kB sites is also unlikely to be responsible for the observed inhibitory eect. This suggests that inhibition of DNA binding, and not inhibition of nuclear localization or competition for DNA binding, may be an important component of the inhibitory activities that we have observed.
The mechanisms by which p80HT loses the inhibitory eects on RelA activation that are associated with p100 NF-kB-2 expression were of considerable interest, as this eect was quite signi®cant and reproducible. The fact that substitution of alanine residues for the serines resulted in complete repression, suggested that either the actual serine residues or the change of the C-terminal tail of p80HT (perhaps due to phosphorylation of the serines) could be responsible for the loss of inhibition of NF-kB activation. The SAS residues at the C-terminus of p80HT do form part of a potential calmodulin kinase II (Cam KII) phosphorylation site, as previously noted (Thakur et al., 1994) , although we have been unable to demonstrate in vitro phosphorylation of this site using puri®ed Cam KII and a bacterially-produced, GST-p80HT fusion protein (data not shown). Nonetheless, we wished to examine whether substitution of the charged aspartic acid residues (as a partial mimetic of phosphoserines) for the two serine residues (aa666DAD) would aect the activity of p80HT. This substitution still resulted in a markedly inhibitory protein, suggesting that charge alone was not responsible, or that the single charges provided by the aspartic acid residues were not sucient to induce a change in p80HT function. Although we do not currently have speci®c biochemical evidence of the mechanism responsible for the loss of repression associated with the p80HT mutation, we hypothesize that the C-terminal serine residues induce a conformational change that may result in loss of interactions of the ankyrin region with nuclear localization and/or DNA binding sequences required for inhibition of NF-kB transcriptional activation.
The mechanisms by which NFKB2 gene alterations may contribute to the development of B-and T-cell lymphomas remain unclear. Two major alternative, and non-exclusive, hypotheses can be proposed. The ®rst hypothesis is that the altered NF-kB-2 proteins have acquired novel properties that contribute to lymphoid transformation. In this case, the altered NFKB2 allele may act as a dominant oncogene, consistent with the reported ability of Lyt10/Ca to transform Balb 3T3 cells, albeit at a low eciency (Ciana et al., 1997) . This model is also consistent with the reported gain of transcriptional activity seen with either Lyt10/Ca and p80HT, as well as that seen with a chimeric p52 molecule in which sequences from the bacterial tetracycline repressor gene were fused to Cterminal p52 sequences (Chang et al., 1995) . The second hypothesis is that the loss of the wild-type p100 NF-kB-2, and its IkB-like, inhibitory activity, plays an important role in transformation. In fact, p100 NF-kB-2 has been shown to function as the major IkB activity in certain cell lines, including some breast adenocarcinoma cells (Dejardin et al., 1999) . This latter model would be consistent with the complete loss of p100 NF-kB-2 seen in the HUT78 CTCL cells, as well as with the lymphoid hyperplasia observed in mice in which targeted gene deletions were performed to`knock-out' p100 while retaining p52 gene expression (Ishikawa et al., 1997) . A model invoking loss of IkB-like activity would also be consistent with older reports that inhibition of IkBa by antisense approaches resulted in transformation of NIH3T3 cells (Beauparlant et al., 1994) , and with reports of IkBa mutations in patients with Hodgkin's disease (Cabannes et al., 1999; Krappmann et al., 1999; Wood et al., 1998) . This model is also reminiscent of one reported mechanism by which HTLV-1 Tax leads to increased NF-kB activity (Kanno et al., 1994) . In this model, Tax induces disruption of p100-containing complexes in the cytoplasm of T cells, leading to constitutive NF-kB activation. In this regard it is interesting to note the many phenotypic similarities between CTCL, associated with NF-kB-2 alterations, and HTLV-1-associated adult T cell leukemia/lymphoma (Nagatani et al., 1994) .
Our data examining the activities of mutated NF-kB-2 proteins associated with lymphomas fail to clearly distinguish between the two models and in fact suggest that dierent mechanisms may be operative in dierent tumors. None of the tumor-associated mutations demonstrated a clear, independent transcriptional activation phenotype for the promoters that we studied, however, we cannot rule out enhanced transcriptional activation of a subset of NF-kB target genes, which would be consistent with previous reports of the transcriptional activity NF-kB-2 proteins containing heterologous C-terminal sequences (Chang et al., 1995) . In more recent studies in our laboratory, inducible expression of p80HT in Jurkat T cells was associated with an apparent resistance to cell death-inducing stimuli (R Sargent, K-E Kim, and AB Rabson, in preparation), suggesting that there are likely to be p80HT inducible target genes that mediate this eect. On the other hand, our data strongly support a role for loss of inhibition of NF-kB-mediated gene expression. A selective loss of the IkB-like activities of p100 does appear to be a common feature of the NF-kB-2 C-terminal truncations associated with tumors. It should be noted that NF-kB-2 mutations are likely to be only one of several mutations involved in the generation of human T-or B cell lymphomas. The HUT78 cell line also contains alterations in c-myc (Finger et al., 1988), c-cbl (Blake and Langdon, 1992) , and p53 (Tolomeo et al., 1998) . Furthermore, alterations in JAK/STAT signaling have also been strongly implicated in the pathogenesis of human CTCL (Nielsen et al., 1997; Zhang et al., 1996) . Loss of the IkB-like activity of p100 NF-kB-2 could lead to enhanced anti-apoptotic activity in these cells as a result of constitutive NF-kB activity (Beg and Baltimore, 1996; Liu et al., 1996; Sonenshein, 1997; Van Antwerp et al., 1996; Wang et al., 1996) . Further studies of additional tumor-associated mutations of NFKB2, as well as detailed studies of altered NF-kB target gene expression will be required to further elucidate the mechanisms by which altered NFKB2 products contribute to the development of CTCL and other lymphomas.
Materials and methods

Cell culture
Human teratocarcinoma N-tera 2 cells were obtained from the American Type Culture Collection and maintained in McCoy's 5A medium (Gibco ± BRL) supplemented with 10% fetal bovine serum (Gemini), at 378C in 5% CO 2 . COS7 cells and HeLa cells were maintained in Dulbecco's modi®ed Eagle medium (Gibco ± BRL) supplemented with 10% fetal bovine serum and grown at 378C under 5% CO 2 .
NF-kB-2 expression plasmids
The p100 NF-kB2 cDNA sequence was isolated as an EcoRI/ XbaI fragment from pSelLytT7comp (Thakur et al., 1994) .
The p80HT cDNA sequence was isolated as an EcoRI/EcoRI fragment form pSelLytl (Thakur et al., 1994) . The p52 cDNA was isolated as an EcoRI/XhoI fragment form pATc21 (Thakur et al., 1994) . pcDNA1/p100, pcDNA1/p80HT, and pcDNA1/p52 were constructed by directly ligating the above fragments into pcDNAIAmp (Invitrogen) followed by transformation. PCR was utilized to generate the NF-kB2 p100 C-terminal truncation mutants. The 5' primer was common to all PCR reactions and encompasses the unique XhoI site which maps to glycine-rich hinge region. The sequence of the 5' primer was 5'-AGCGAGCTCGAGAG-TACA-3', including an XhoI restriction site. All the 3' primers contained a stop codon followed by an XbaI site. The sequence of each 3' primer used for PCR ampli®cation was: aa490; 5'-GCTCTAGATTATGTGTCTCCGTTCTC-GTC-3', aa552; 5'-GCTCTAGATTAGTCTGCACCTCCCG-CAG-3', aa605; 5'-GCTCTAGATTAGTGTACTGGATA-CAGTCC-3', aa625; 5'-GCTCTAGATTATTCAGCCCCA-CTGTCCAC-3', aa659; 5'-GCTCTAGATTAGGCCCG-GAGCTTGGTGAC-3', aa666; 5'-GCTCTAGATTAAAAG-GTGCGAGCGTTCAC-3', aa666AAA; 5'-GCTCTAGAT-TATGCTGCCGCAAAGGTGCGAGCGTTCAC-3', aa666-DAD; 5'-GCTCTAGATTAATCGGCATCAAAGGTGCG-AGCGTTCACGTTGG-3', LB40; GCTCTAGATTACAG-GGGCTCCTCGTTTTC-3'.
The PCR fragments were digested with XhoI/XbaI and ligated into XhoI/XbaI-digested pcDNA1/p52. pcDNA1/ EB308 was reconstructed by PCR ampli®cation to regenerate the 3' sequence of EB308 cDNA. The same 5' primer including the XhoI site was used. The sequence of the 3' primer was constructed to regenerate the additional 12 amino acids present in the fusion domain of EB308 following amino acid 604 of p100, and had the sequence: 5'-AGCTCTAGAT-CACTG TGTTAGCC AAGATGGTCTTG ATCTCCTGAC-CTCGTGTACTGGATACAG-3'.
The PCR product was digested with XhoI/XbaI and ligated into XhoI/XbaI-cleaved pcDNAI/p52. The sequence of the PCR ampli®ed region of each mutated NF-kB-2 molecule was by dideoxy chain termination method (Sanger et al., 1977) . The Lyt10-Ca-expression plasmid, pHCMV lyt10Ca, was kindly provided by Dr Riccardo Dalla-Favera (Columbia University, New York, NY, USA). The pCMV-p65RelA expression vector (Ruben et al., 1992) was a kind gift of Dr C Rosen.
Promoter and reporter gene plasmids
Plasmids containing the P1 and P2 NFKB2 promoter sequences were constructed by PCR ampli®cation of segments derived from a genomic clone of the NFKB2 gene. Approximately 1610 6 phage from a human placental genomic lambda library (Clontech) were screened with a 262 bp probe derived from the 5' end of the NFKB2 cDNA (714 to +248 bases from the translational start codon), using plaque hybridization as previously described (Martin et al., 1981) . One positive phage was isolated. By restriction enzyme mapping, DNA sequences mapping close to the published 5' end of the cDNA were identi®ed. A 5 kb HindIII fragment was subcloned (pEV1), and DNA sequence analysis was performed by dideoxynucleotide chain termination method (Sanger et al., 1977) . A 586 bp segment representing the core elements of the P1 promoter (Liptay et al., 1994; Lombardi et al., 1995) was ampli®ed by PCR using a 5' oligonucleotide primer beginning at 7586 bp with respect to the major P1 start site and containing a HindIII restriction enzyme site, with the sequence: 5'-CCCAAGCTTTCCCGGAGCCTTGAGGCT-GA-3'; and a 3' oligonucleotide primer extending from the +70 bp position of the P1 promoter, containing and XbaI restriction enzyme site, and having the sequence: 5'-CGTCTAGAGCTAAAGGCCCTCCTCCCTC-3'. The ampli®ed DNA was ligated to the HindIII and XbaI sites upstream of the CAT (chloramphenicol acetyl transferase) reporter gene in the pCAT vector (Promega) to construct P1 CAT. The P1-luciferase reporter plasmid was constructed by isolating the luciferase open reading frame from pGL3-Basic vector (Promega) by NheI and HpaI digestion and subsequent ligation into P1-CAT plasmid digested with XbaI and HpaI.
A 624 bp P2 promoter segment was ampli®ed by PCR from the plasmid clone of genomic segment of the NFKB2 promoter. The P2 promoter is complex and has been shown to contain multiple mRNA start sites (Liptay et al., 1994; Lombardi et al., 1995) . The cloned P2 segment used for these experiments mapped from 7455 bp (Liptay et al., 1994) or 7540 bp 5' to the alternative upstream transcriptional start sites observed for the P2 promoter at positions +149 (Liptay et al., 1994) or +84 with respect to the previously reported upstream transcription start sites. Primers used for PCR included PstI and XbaI restriction enzyme sites and were: 5' primer: 5'-CCCTGCAGTCTAGAGAGCGTGCAG-AGATCTCC-3'; 3' primer: 5'-CCCTGCAGTCTAGAATCC-GGAGTTGGGCTTGG-3'.
The ampli®ed P2 promoter segment was digested with XbaI and ligated into XbaI cleaved pCAT (Promega). The P selectin-luciferase reporter gene plasmid (Pan and McEver, 1995) was kindly provided by Dr R McEver (University of Oklahoma, Oklahoma City, OK, USA).
Transfections and reporter assays
N-tera 2 cells were transfected using Lipofectin as suggested by the manufacturer (Gibco BRL) and COS7 cells were transfected by calcium phosphate precipitation by standard methods (Graham and Van der Eb, 1973) . CAT lysates were collected 48 h post-transfection and luciferase lysates were obtained after 38 h post-transfection. CAT assay was performed as previously described (Gorman et al., 1982) , using equal amounts of cell lysates as measured by Bradford assay (Bradford, 1976) . Luciferase assay was performed as described by the manufacturer (Promega) using a luminometer (Turner Designs, TD-20/20) and the activity was normalized to protein concentration of the cell lysates as measured with BCA protein measurement kit (Pierce). All transfections were done in triplicate and the total amount of transfected CMV promoter DNA was maintained constant by adding the appropriate amount of pcDNA1Amp, the empty expression vector. HeLa cells were transfected using LipofectAMINE as suggested by the manufacturer (Gibco BRL).
Western blot
COS7 cells and HeLa cells were harvested 48 h posttransfection and 30 mg of the lysates were separated by electrophoresis through 10% SDS ± PAGE, followed by transfer to a nitrocellulose membrane (Schleicher and Schuell) and incubation with monoclonal anti-human NFkB2 p52 antibody (Upstate Biotechnology Cat# 05-361) at 1 : 1000 dilution. The secondary antibody was an anti-mouse IgG from sheep (Amersham, Cat# NXA931) used at 1 : 10 000 dilution and the signals were detected by ECL (Amersham). In vitro translated proteins were electrophoresed through 10% SDS ± PAGE, transferred to a nitrocellulose membrane, and incubated with monoclonal anti-human NF-kB2 p52 antibody, and the signals were detected by ECL. assistance with plasmid preparations and screening, F Foss, F Payvandi, J Suh, A Ramakrishnan, C Chen, and W-X Zhang for helpful discussions, and Dr C GeÂ linas for suggestions and critical reading of the manuscript. This work was supported by National Institutes of Health, NCI grant CA 68333.
